Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Olokizumab in Rheumatoid Arthritis
NCT01296711Phase 2Terminated
- Sponsor
- UCB
- Start
- Mar 2011
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of olokizumab in rheumatoid arthritis (RA), sponsored by UCB. Started Mar 2011; status: terminated.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01296711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01296711.